Clinical Trials Logo

Metastatic Colo-rectal Cancer clinical trials

View clinical trials related to Metastatic Colo-rectal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT01867918 Terminated - Clinical trials for Metastatic Colo-rectal Cancer

LOTCOL Study: Local Treatment of Colo-rectal Liver Met

LOTCOL
Start date: May 2013
Phase: N/A
Study type: Interventional

In this study the investigators will include colo-rectal cancer (CRC) patients starting last line of standard palliative chemotherapy. Eligible patients include patients with KRAS mutation starting line or KRAS wild type starting line treatment. Standard treatment today for these patients is chemotherapy only and median overall survival (OS) is about 10 months. The hypothesis is that local treatment in addition to systemic treatment will increase time to progression, progression free survival and overall survival compared to patients who receive systemic chemotherapy only. The investigators experience with local treatment of liver metastases in CRC patients is that side-effects of treatment in general are minor, although gastric bleeding have been observed after stereotactic body radiation therapy.

NCT ID: NCT01358812 Completed - Clinical trials for Metastatic Colo-rectal Cancer

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

TRIP
Start date: March 2010
Phase: Phase 2
Study type: Interventional

The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in molecularly selected metastatic colo-rectal cancer patients.